MANIV
4.4.2024 17:21:27 CEST | Business Wire | Press release
Maniv, a global venture capital firm based in Tel Aviv and NYC, today announces the closing of its third fund, an $140m vehicle to invest in Seed and Series A stage startups that brings the firm’s assets under management to nearly $320m.
Investing since 2016, Maniv was among the first institutional investors to articulate a global, early-stage investment strategy focused on the intersection between mobility, transportation and energy. Maniv invests in deep technologies and business model innovations around two central themes:
The movement of people and goods continues to be marked by analog processes and data-poor operating environments. From manufacturing to fulfillment and logistics, vehicle access, maintenance and repair, insurance, fleet management, and more, startups are driving the digitization of transportation’s value chains across land, sea, and air. Simultaneously, the market-driven decarbonization of transportation – representing as much as one quarter of global GHG emissions – is at an inflection point. Private sector incentives are tipping towards clean propulsion, a process accelerated by brisk regulatory tailwinds worldwide. These seismic shifts create a massive opportunity for startups to advance new technologies, form factors, business models, and platforms.
Maniv has already made four investments out of the new fund. Celadyne, based in Chicago, extends the lifespan and efficiency of proton-exchange membranes to make green hydrogen production financially viable. Neologic, based in Israel, introduces a proprietary chip design for dramatic performance and power gains in data centers, automotive and beyond. Circular, based in San Francisco, mainstreams post-consumer recycled plastics adoption in manufacturing, by closing pervasive information and testing gaps. Vammo, based in São Paulo, is electrifying LATAM’s B2B two-wheeler market, by orchestrating vehicles, financing, and a ubiquitous battery swapping network.
From its first two, top-performing funds, Maniv led investments in breakout companies including AI edge silicon scaleup Hailo from Tel Aviv, EV ridehail and charging network Revel from New York, medium-duty EV truckmaker Harbinger Motors from Los Angeles, intercity bussing platform Kolors from Mexico City, two-wheeler EV OEM River from Bangalore, and Madrid-based car subscription startup Bipi, acquired by Renault’s financing arm RCI Banque in 2021.
Maniv’s third fund is backed by institutional capital, high-net-worth individuals, and a consortium of industry leaders at the forefront of the transportation sector. Maniv’s prior funds were substantially backed by leading carmakers and Tier-1 suppliers. Maniv III maintains those automotive partnerships – including return investors Valeo and InMotion Ventures, the investment arm of Jaguar-Land Rover, joined by Woven Capital of Toyota Motor Corp. The new fund has expanded its LP base to reflect critical automotive adjacencies through partners including global vehicle leasing and mobility solutions leader Arval and the automotive finance experts of BNP Paribas Personal Finance of Europe’s leading bank BNP Paribas; Shell Ventures of the global energy giant Shell; global sustainable infrastructure leader Ferrovial; Enterprise Mobility Ventures, the VC arm of Enterprise Mobility; industrial manufacturing leader ITT Inc.; fleet payments leader WEX; a major European insurance company; several major automotive dealer and distributor groups; and more.
“Our third fund builds on two decades in the trenches of the global mobility ecosystem,” said Michael Granoff, the firm’s Managing Partner. “Maniv has built a platform to summon the best of two worlds – the agility of a traditional VC, and close proximity to the underlying industries surrounding mobility and transportation. We believe we are uniquely structured to leverage our deep institutional memory and access to industry decision-makers, for the benefit of our portfolio companies and ultimately our investors. Announcing this new vehicle amidst a backdrop of geopolitical uncertainty and shaky private markets is a testament to the resilience of the sector and our strategy.”
“Maniv’s mandate is to deliver outsized returns by joining forces with those rare entrepreneurs with both the vision and tenacity to drive the transportation sector into the 21st century,” added Nate Jaret, General Partner at Maniv. “Human prosperity depends on the seamless and sustainable movement of people and goods; mobility continues to represent a generational opportunity for entrepreneurs and investors alike.”
“When we met Maniv, we had spoken to over 100 investors and operators of electric mobility around the world and nobody – repeat nobody – was more knowledgeable about the space than the Maniv team,” said Jack Sarvary, Co-founder & CEO of portfolio company Vammo based in São Paulo. “Getting them not just onto our cap table but also our board quickly became a priority.”
"From the outset it was clear that Maniv is deeply connected to forward-thinking mobility players,” said Ian Arthurs, Founder & CEO of portfolio company Circular. “Within weeks of our first conversation, the Maniv team found us new enterprise partners and customers in the auto space, which would have taken us months to figure out on our own.”
Website: www.maniv.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404972652/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
